ChestLink

Oxipit
ChestLink is the first fully autonomous AI medical imaging product with a CE mark. ChestLink identifies CXRs with no abnormality and produces finalized patient reports without any intervention from the radiologist, reducing radiologist workload and enabling them to focus on cases with pathologies.
Information source: Vendor
Last updated: Nov. 23, 2023

General Information

General
Product name ChestLink
Company Oxipit
Subspeciality Chest
Modality X-ray
Disease targeted Algorithms support 75 different pathologies
Key-features Autonomous healthy patients report generation
Suggested use Without interference of a radiologist: AI-only diagnosis

Technical Specifications

Data characteristics
Population Older than 18 years old
Input PA or PA + LAT Digital Chest X Ray
Input format DICOM
Output Report for healthy patients
Output format DICOM SR or HL7 message
Technology
Integration Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration via AI marketplace or distribution platform
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically, right after the image acquisition
Processing time 10 - 60 seconds

Regulatory

Certification
CE
Certified, Class IIb , MDR
FDA No or not yet
Intended Use Statements
Intended use (according to CE) ChestLink automatically and autonomously (without the involvement of a radiologist) evaluates a chest X-ray study. The software is indicated to automatically detect actionable radiological findings on chest radiographs. After this analysis, one of two actions is performed: (1) If ChestLink is confident that a study has no actionable radiological findings, a report is automatically generated. The study is not reported on by a trained radiologist. (2) If ChestLink cannot confidently rule out the presence of actionable radiological findings, the study is directed to be reported on by a radiologist.

Market

Market presence
On market since 03-2022
Distribution channels Alma AI MARKETPLACE, Sectra Amplifier Store, CARPL.ai
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model Pay-per-use, Subscription
Based on Number of analyses

Evidence

Evidence
Peer reviewed papers on performance

  • Commercially Available Chest Radiograph AI Tools for Detecting Airspace Disease, Pneumothorax, and Pleural Effusion (read)

  • Autonomous Chest Radiograph Reporting Using AI: Estimation of Clinical Impact (read)
Non-peer reviewed papers on performance

  • USING ARTIFICIAL INTELLIGENCE TO DETECT CHEST X-RAYS WITH NO SIGNIFICANT FINDINGS IN A PRIMARY HEALTH CARE SETTING IN OULU, FINLAND (read)
Other relevant papers